<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1117">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04600440</url>
  </required_header>
  <id_info>
    <org_study_id>Covid convalescent plasma</org_study_id>
    <nct_id>NCT04600440</nct_id>
  </id_info>
  <brief_title>Convalescent Plasma in the Treatment of Covid-19</brief_title>
  <acronym>COP20</acronym>
  <official_title>Convalescent Plasma in the Treatment of Covid-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Skane University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      One hundred patients hospitalized and in need of oxygen treatment due to Covid-19 should be&#xD;
      randomized and 50% treated with 200 ml convalescent plasma x 3 and 50% given ordinary&#xD;
      treatment.&#xD;
&#xD;
      Primary outcome is number of days the patients need oxygen within 28 days from inclusion.&#xD;
&#xD;
      Secondary outcome is number of days in hospital, number of days in respirator and mortality.&#xD;
&#xD;
      Side effects of treatment is monitored.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with previous verified COVID-19 are asked to donate plasma 14 days or later after&#xD;
      recovery. IgG antibodies against Covid-19 are measured and only subjects with high titers are&#xD;
      accepted. Plasmaphereses is done and up to 600 ml plasma is drawn and aliquoted in 200 ml&#xD;
      portions.&#xD;
&#xD;
      Patients with acute respiratory symptoms, verified Covid-19, hospitalized and in need of&#xD;
      oxygen treatment are asked to participate in the study. The patients are randomized 50/50 to&#xD;
      get either convalescent plasma or routine treatment without plasma. The patients randomized&#xD;
      to get plasma will have infusion of 200 ml blood group compatible convalescent plasma daily&#xD;
      during three days from different donors.&#xD;
&#xD;
      The clinical course will be carefully monitored and days with oxygen requirement will be&#xD;
      compared between the groups. Secondary clinical outcomes as mortality, need of assisted&#xD;
      ventilation, total days in hospital and side effects to treatment will be observed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days in need of oxygen</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days in need of oxygen within 28 days from inclusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of days before discharge from hospital</measure>
    <time_frame>3 months</time_frame>
    <description>number of days before discharge from hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality within 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>death of patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days before need of assisted ventilation</measure>
    <time_frame>28 days</time_frame>
    <description>number of days before need of assisted ventilation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Covid-19</condition>
  <condition>Respiratory Insufficiency</condition>
  <arm_group>
    <arm_group_label>Plasma treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Convalescent plasma 200 ml daily during three days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No plasma</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Best conventional treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent plasma</intervention_name>
    <description>Plasma donated from patients recovered from Covid-19 and having high titres of antibodies</description>
    <arm_group_label>Plasma treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Verified diagnosis of Covid-19&#xD;
&#xD;
          -  &lt;94% oxygen saturation&#xD;
&#xD;
          -  willingness to participate&#xD;
&#xD;
          -  ability to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unability to understand information and sign informed consent&#xD;
&#xD;
          -  immunosuppressed patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mona Landin-Olsson, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skane University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria N Lundgren, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Skane University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magnus Rasmussen, MD, Prof</last_name>
    <phone>+4646171000</phone>
    <email>magnus.rasmussen@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mona Landin-Olsson, MD, Prof</last_name>
    <phone>+4646171000</phone>
    <phone_ext>71452</phone_ext>
    <email>mona.landin-olsson@med.lu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sk√•ne University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>SE-22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mona Landin-Olsson, MD, Prof</last_name>
      <phone>+4646171000</phone>
      <phone_ext>71452</phone_ext>
      <email>mona.landin-olsson@med.lu.se</email>
    </contact>
    <contact_backup>
      <last_name>Magnus Rasmussen, MD, Prof</last_name>
      <phone>+4646171000</phone>
      <email>magnus.rasmussen@med.lu.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Skane University Hospital</investigator_affiliation>
    <investigator_full_name>Mona Landin-Olsson</investigator_full_name>
    <investigator_title>MD Prof, Senior consultant</investigator_title>
  </responsible_party>
  <keyword>Covid-19</keyword>
  <keyword>Convalescent plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

